Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 4 fingolimod study in pediatric relapsing multiple sclerosis in China
2024-000601-32Phase 4
- Sponsor
- Novartis
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Annualized relapse rate (ARR).
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-000601-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-000601-32.